NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Volition's Capture-Seq Technology and 180-Fold Enrichment Breakthrough in Liquid Biopsy
TL;DR
VolitionRx's new Capture-Seq method offers a potential edge in cancer detection with 100% accuracy in early trials, creating opportunities for licensing and portfolio expansion.
VolitionRx's Capture-Seq method analyzes transcription factor-protected DNA fragments in blood by focusing on chromosomal context, achieving 180-fold enrichment to overcome background noise in liquid biopsies.
This technology could improve cancer detection and monitoring, potentially saving lives through earlier diagnosis and better treatment outcomes for patients worldwide.
VolitionRx discovered a way to detect cancer with perfect accuracy in initial tests by analyzing tiny DNA fragments that transcription factors protect in blood.
Found this article helpful?
Share it with your network and spread the knowledge!
Volition has developed Capture-Seq™, a new method that achieves 180-fold (18,000%) enrichment of transcription factor-bound ultrashort DNA fragments in blood, solving liquid biopsy's "needle in a haystack" problem of overwhelming background DNA.
Capture-Seq™ focuses on analyzing DNA in its natural chromosomal context rather than chemically extracted DNA, which allows for much more effective isolation of transcription factor-protected fragments from the background DNA in blood samples.
Early findings from a 70-person training cohort showed 100% sensitivity and 100% specificity across several cancers, including early-stage disease, demonstrating the promise of this new biomarker class.
This technology enables the detection of cancer biomarkers in blood with unprecedented accuracy, potentially allowing for earlier detection of cancer when it's more treatable, through a simple, low-cost liquid biopsy.
Volition is a multi-national epigenetics company focused on developing simple, cost-effective blood tests to detect and monitor diseases including cancer. This breakthrough could expand their Nu.Q® portfolio and lead to commercial applications.
Volition is developing two patent-pending technologies to isolate ultrashort DNA fragments and is in discussions with potential licensing partners as it explores commercial applications.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
The technology could help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis, through simple blood tests.
The preprint manuscript titled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq" is available, and more information can be found at Volition's website at www.Volition.com.
Early detection and monitoring through this technology have the potential not only to prolong patients' lives but also to improve their quality of life by enabling earlier intervention and treatment.
Curated from InvestorBrandNetwork (IBN)
